Check out BioWorld Today’s extensive coverage on the impact of the partial government shutdown.

Now that the government has returned to business, agencies will have to deal with clearing a logjam of applications and agenda items that have been piling up during the hiatus. For example, the FDA will have to process all the fiscal 2014 establishment and product fees that were due Oct. 1, while tending to the drug and biologic applications and sponsor requests for meetings that have been idling. Elsewhere, the Patent and Trademark Office, which has remained open during the appropriations lapse, has pushed its Oct. 30 public meeting on copyright policy issues back to Dec. 12, citing complications arising from the government closure.

The FDA rolled out two guidance documents: One is a revision of a 2010 draft on developing direct-acting antiviral drugs to treat hepatitis C; the second is a draft guidance on the development of drugs to treat acute bacterial skin and skin structure infections.